02.12.24 -- A Future Renaissance At Catalent? Employees Think So

Protein A chromatography is a key bottleneck in mAb manufacturing. Precipitation, an early separation technique, has emerged as a ready solution for continuous manufacturing.

The key to navigating the biologic development journey lies in CMC. By analyzing and characterizing the drug's properties, CMC teams ensure a smooth path from bench to patient care.

The future of conjugation and PEGylation in biologics is promising, with advancements focused on enhancing drug efficacy and reducing immunogenicity. Understand the key focus areas for PEGylated proteins.

Examine the drivers behind the recent successes in the clinic, current challenges with development and manufacturing, and what the future might hold for the ADC industry.

As biologics manufacturers aim for cGMP compliance, explore the challenges of incorporating cGMP standards and how to foster a culture of product quality throughout all levels of your organization.

New higher volume, higher viscosity pharmaceutical formulations for subcutaneous injection, alternatives to traditional intravenous treatment, enable chronic disease therapy in alternate settings.

Selecting the right manufacturing partner with appropriate lyophilization expertise, experience, and analytical capabilities can speed drug development and expedite time-to-market for lyophilized drugs.

Outsourcing to a CTDMO is a promising solution for companies lacking the technical expertise and in-house capacity to address biomanufacturing challenges. Learn why selecting the right CTDMO partner is vital for project success.

Lonza’s Drug Product Services delivers a holistic approach to DP development that prevents problems early and produces a product that is fit for purpose.

Learn how a reliable and agile partner that enables seamless scalability and accelerated development can help you navigate the journey from research and development to clinical trials and beyond.